Browsing
     by title


0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

or enter first few letters:   
OK
Full Text
See detailEquipes éducatives, équipes thérapeutiques en pédopsychiatrie
Labar, P.; Chapelle, M. P.; Philippart, D. et al

in Feuillets Psychiatriques de Liège (1984), 17(1/2), 7-13

Detailed reference viewed: 17 (0 ULg)
See detailL'equità dei sistemi scolastici europei
Demeuse, Marc; Baye, Ariane ULg; Straeten, Marie-Hélène

in Bottani, N.; Benadusi, L. (Eds.) Uguaglianza e equità nella scuola (2006)

Detailed reference viewed: 5 (3 ULg)
See detailL'équité des systèmes éducatifs européens. Un ensemble d'indicateurs
Baye, Ariane ULg; Benadusi, L.; Bottani, G. et al

Report (2005)

Detailed reference viewed: 27 (0 ULg)
Peer Reviewed
See detailL'équité des systèmes éducatifs, une question de point de vue
Baye, Ariane ULg

Conference (2002)

Detailed reference viewed: 2 (1 ULg)
See detailEquité et efficacité du système belge de santé
Fecher-Bourgeois, Fabienne ULg

Scientific conference (2013, February 25)

Detailed reference viewed: 9 (0 ULg)
See detailEquité et efficacité du système d’enseignement
Baye, Ariane ULg

Conference given outside the academic context (2008)

Detailed reference viewed: 10 (1 ULg)
See detailEquité et efficacité du système d'enseignement
Baye, Ariane ULg

in Le défi social bruxellois, un déficit de qualification, l'école en question (2008)

Detailed reference viewed: 17 (5 ULg)
Peer Reviewed
See detailEquity in Education: A typology of European Educational Systems
Baye, Ariane ULg

Conference (2005, April 13)

Detailed reference viewed: 4 (1 ULg)
See detailEquity in European Education Systems
Baye, Ariane ULg; Benadusi, L.; Bottani, N. et al

Report (2005)

Detailed reference viewed: 6 (3 ULg)
Full Text
Peer Reviewed
See detailEquity in European Educational System. A set of indicators
Baye, Ariane ULg; DEMEUSE, MARC; NICAISE, JULIEN et al

in European Educational Research Journal (2005), 4(2), 1-151

Detailed reference viewed: 61 (9 ULg)
See detailEquity in European Educational Systems. A set of indicators
Baye, Ariane ULg; Demeuse, Marc; Nicaise, Julien et al

Book published by department of Theoretical and Experimental Education- University of Liège - 2nd Edition (2005)

Detailed reference viewed: 3 (0 ULg)
See detailEquity in INES Network B indicators: a Review
Baye, Ariane ULg

Scientific conference (2004, February 09)

Detailed reference viewed: 11 (0 ULg)
See detailEquity indicators in the field of continuous education and training
Baye, Ariane ULg

Scientific conference (2004, November 08)

Detailed reference viewed: 12 (0 ULg)
Full Text
Peer Reviewed
See detailEquity of achievement : A matter of education structures ?
Baye, Ariane ULg; Monseur, Christian ULg

in The Second IEA International Research Conference : Proceedings of the IRC-2006 (2007)

Detailed reference viewed: 47 (24 ULg)
See detailEquity of the European Educational Systems. A set of indicators. Synthesis of the report.
Demeuse, Marc; Baye, Ariane ULg; Straeten, Marie-Hélène et al

Book published by Université de Liège, Service de Pédagogie expérimentale (2003)

Detailed reference viewed: 16 (0 ULg)
Full Text
Peer Reviewed
See detailEquivalence associée à la relation de conformité "conf" et simplification du testeur canonique en LOTOS
Leduc, Guy ULg

in Rafiq, Omar (Ed.) CFIP'91 Ingénierie des Protocoles (1991, September)

Detailed reference viewed: 14 (0 ULg)
Full Text
Peer Reviewed
See detailEquivalence of a single dose (1200 mg) compared to a three-time a day dose (400 mg) of chondroitin 4&6 sulfate in patients with knee osteoarthritis. Results of a randomized double blind placebo controlled study.
Zegels, Brigitte ULg; Crozes, P.; Uebelhart, D. et al

in Osteoarthritis and Cartilage (2013), 21(1), 22-27

OBJECTIVE: Evaluation of the efficacy and safety of a single oral dose of a 1200 mg sachet of chondroitin 4&6 sulfate (CS 1200) vs three daily capsules of chondroitin 4&6 sulfate 400 mg (CS 3*400 ... [more ▼]

OBJECTIVE: Evaluation of the efficacy and safety of a single oral dose of a 1200 mg sachet of chondroitin 4&6 sulfate (CS 1200) vs three daily capsules of chondroitin 4&6 sulfate 400 mg (CS 3*400) (equivalence study) and vs placebo (superiority study) during 3 months, in patients with knee osteoarthritis (OA). DESIGN: Comparative, double-blind, randomized, multicenter study, including 353 patients of both genders over 45 years with knee OA. Minimum inclusion criteria were a Lequesne index (LI) >/= 7 and pain >/= 40 mm on a visual analogue scale (VAS). LI and VAS were assessed at baseline and after 1-3 months. Equivalence between CS was tested using the per-protocol procedure and superiority of CS vs placebo was tested using an intent-to-treat procedure. RESULTS: After 3 months of follow-up, no significant difference was demonstrated between the oral daily single dose of CS 1200 formulation and the three daily capsules of CS 400. Patients treated with CS 1200 or CS 3*400 were significantly improved compared to placebo after 3 months of follow-up in terms of LI (<0.001) and VAS (P < 0.01). No significant difference in terms of security and tolerability was observed between the three groups. CONCLUSION: This study suggests that a daily administration of an oral sachet of 1200 mg of chondroitin 4&6 sulfate allows a significant clinical improvement compared to a placebo, and a similar improvement when compared to a regimen of three daily capsules of 400 mg of the same active ingredient. [less ▲]

Detailed reference viewed: 14 (9 ULg)
Full Text
Peer Reviewed
See detailEquivalence of indapamide SR and enalapril on microalbuminuria reduction in hypertensive patients with type 2 diabetes: The NESTOR* study
Marre, Michel; Garcia Puig, Juan; Kokot, Franciszek et al

in Journal of Hypertension (2004), 22(8), 1613-1622

Objectives To test whether microalbuminuria in patients with type 2 diabetes and hypertension is primarily dependent on the severity of hypertension, and to compare the effectiveness of two anti ... [more ▼]

Objectives To test whether microalbuminuria in patients with type 2 diabetes and hypertension is primarily dependent on the severity of hypertension, and to compare the effectiveness of two anti hypertensive drugs with opposite effects on the renin-angiotensin system [the diuretic, indapamide sustained release (SR), and an angiotensin-converting enzyme inhibitor, enalapril] in reducing microalbuminuria. Design A multinational, multicentre, controlled, double-blind, double-dummy, randomized, two-parallel-groups study over 1 year. Methods After a 4-week placebo run-in period, 570 patients (ages 60.0 +/- 9.9 years, 64% men) with type 2 diabetes, essential hypertension [systolic blood pressure (SBP) 140-180 mmHg, and diastolic blood pressure (DBP) < 110 mmHg], and persistent microalbuminuria (20-200 mu g/min) were allocated randomly to groups to receive indapamide SR 1.5 mg (n = 284) or enalapril 10 mg (n = 286) once a day. Amlodipine, atenolol, or both were added, if necessary, to achieve the target blood pressure of 140/85 mmHg. Results There was a significant reduction in the urinary albumin: creatinine ratio. Mean reductions were 35% [95% confidence interval (Cl) 24 to 43] and 39% (95% Cl 30 to 47%) in the indapamide SR and enalapril groups, respectively. Equivalence was demonstrated between the two groups [1.08 (95% Cl 0.89 to 1.31%); P = 0.01]. The reductions in mean arterial pressure (MAP) were 16.6 +/- 9.0 mmHg for the indapamide SR group and 15.0 +/- 9.1 mmHg for the enalapril group (NS); the reduction in SBP was significantly greater (P = 0.0245) with indapamide SR. More than 50% of patients in each group required additional antihypertensive therapy, with no differences between groups. Both treatments were well tolerated. Conclusions lndapamide-SR-based therapy is equivalent to enalapril-based therapy in reducing microalbuminuria with effective blood pressure reduction in patients with hypertension and type 2 diabetes. [less ▲]

Detailed reference viewed: 46 (0 ULg)